Full Press Release Details
SAN DIEGO , Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN ) announced that the company will divest GRAIL.
The divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission's divestiture order, with the goal of finalizing the terms by the end of the second quarter of 2024.
"We are committed to an expeditious divestiture of GRAIL in a manner that allows its technology to continue benefitting patients," said Jacob Thaysen , CEO of Illumina. "The management team and I continue to focus on our core business and supporting our customers. I am confident in Illumina's opportunities and our long-term success."
Cautionary Note on Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties.
Cautionary Note on Statements of Opinion In addition to forward-looking statements, this release contains statements of opinion with which all may not agree.
About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X (Twitter) , Facebook , LinkedIn , Instagram , TikTok and YouTube .
Investors: Salli Schwartz 858-291-6421 [email protected]
Media: David McAlpine 347-327-1336 [email protected]
SOURCE Illumina, Inc.